| Gender, n (%) | |
| Female | 20 (45) |
| Male | 24 (55) |
| Age, median (range), y | 54 (35-72) |
| History of celiac disease, n (%) | 25 (57) |
| Disease stage at dx (Ann Arbor), n (%) | |
| I | 9 (20) |
| II | 14 (32) |
| IV | 19 (43) |
| Data missing | 2 (5) |
| B-symptoms at dx, n (%) | 22 (54) |
| Initial therapy | |
| CHOP | 18 (43) |
| CHOP/IVE/MTX | 4 (9)* |
| CHOEP | 4 (9) |
| ACVBP | 3 (7) |
| IVE | 3 (7) |
| Other/unknown | 12 (27) |
| Antibody included | 2 (5) |
| No. of treatment lines before ASCT, n (%) | |
| 1 | 19 (46) |
| 2 | 15 (34) |
| >2 | 4 (9) |
| Data missing | 4 (9) |
| Time from dx to ASCT, median (range), mo | 6 (3-32)† |
| Disease status at transplant, n (%) | |
| CR or PR1 | 31 (70) |
| More advanced | 13 (30)‡ |
| High-dose regimen, n (%) | |
| BEAM | 36 (82) |
| TBI | 4 (9) |
| Stem cell source PB, n (%) | 44 (100) |
| Gender, n (%) | |
| Female | 20 (45) |
| Male | 24 (55) |
| Age, median (range), y | 54 (35-72) |
| History of celiac disease, n (%) | 25 (57) |
| Disease stage at dx (Ann Arbor), n (%) | |
| I | 9 (20) |
| II | 14 (32) |
| IV | 19 (43) |
| Data missing | 2 (5) |
| B-symptoms at dx, n (%) | 22 (54) |
| Initial therapy | |
| CHOP | 18 (43) |
| CHOP/IVE/MTX | 4 (9)* |
| CHOEP | 4 (9) |
| ACVBP | 3 (7) |
| IVE | 3 (7) |
| Other/unknown | 12 (27) |
| Antibody included | 2 (5) |
| No. of treatment lines before ASCT, n (%) | |
| 1 | 19 (46) |
| 2 | 15 (34) |
| >2 | 4 (9) |
| Data missing | 4 (9) |
| Time from dx to ASCT, median (range), mo | 6 (3-32)† |
| Disease status at transplant, n (%) | |
| CR or PR1 | 31 (70) |
| More advanced | 13 (30)‡ |
| High-dose regimen, n (%) | |
| BEAM | 36 (82) |
| TBI | 4 (9) |
| Stem cell source PB, n (%) | 44 (100) |
ACVBP, doxorubicin-cyclophosphamide-vindesine-bleomycin-prednisone; BEAM, carmustine-etoposide-cytosine arabinoside-melphalan; CHOEP, cyclophosphamide-doxorubicin-vincristine-etoposide-prednisone; CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; CR, complete remission; dx, diagnosis; IVE, ifosfamide-etoposide-epirubicin; MTX, methotrexate; PB, peripheral blood; PR, partial remission; TBI, total body irradiation.
Methotrexate included in initial therapy in 8 patients.
Median time 6 months (3-14) in patients transplanted in the first CR or PR and 12 months (4-32) in patients transplanted with more advanced disease status (P = .0036).
Sensitive relapse in 3 patients, unspecified relapse in 2 patients, CR2 in 3 patients, unspecified CR in 1 patient, and PR >1 in 2 patients.